Polyethylene glycol modified fgf21 engineered to maximize potency and minimize vacuole formation

Bioconjugate Chemistry

Volumn 24, Issue 6, 2013, Pages 915-925

  Xu, Jing ^a   Bussiere, Jeanine ^a   Yie, Junming ^a   Sickmier, Allen ^a   An, Phil ^b   Belouski, Ed ^b   Stanislaus, Shanaka ^a   Walker, Kenneth W ^b  

^a Department of Metabolic Disorders ^*  (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; CELL CULTURE; METABOLISM; POLYETHYLENES; PROTEINS;

ENERGY METABOLISM; FIBROBLAST GROWTH FACTOR; HALF LIVES; NATIVE PROTEINS; PEGYLATION; PHARMACEUTICAL PROTEIN; PHYSIOLOGICAL EFFECTS; TUBULAR EPITHELIUM; TYPE II; VACUOLE FORMATION;

POLYETHYLENE GLYCOLS;

FIBROBLAST GROWTH FACTOR 21; GLUCOSE; MACROGOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; BODY WEIGHT; CELL ACTIVITY; CELL VACUOLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG SOLUBILITY; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EPITHELIUM; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84879389894     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300603k     Document Type: Article

References (30)

1. Brown, J. B., Nichols, G..A., and Perry, A. (2004) The burden of treatment failure in type 2 diabetes Diabetes Care 27, 1535-40
2. Itoh, N. (2010) Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease Cell Tissue Res. 342, 1-11
3. Fukumoto, S. (2008) Actions and mode of actions of FGF19 subfamily members Endocr. J. 55, 23-31
4. Holt, J. A., Luo, G., Billin, A. N., Bisi, J., McNeill, Y. Y., Kozarsky, K. F., Donahee, M., Wang, D. Y., Mansfield, T. A., Kliewer, S. A., Goodwin, B., and Jones, S. A. (2003) Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis Genes Dev. 17, 1581-91
5. Nabeshima, Y. (2010) Regulation of calcium homeostasis by alpha-Klotho and FGF23 Clin. Calcium 20, 1677-85
6. Kharitonenkov, A. and Shanafelt, A. B. (2008) Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases BioDrugs 22, 37-44
7. Fon Tacer, K., Bookout, A. L., Ding, X., Kurosu, H., John, G. B., Wang, L., Goetz, R., Mohammadi, M., Kuro-o, M., Mangelsdorf, D. J., and Kliewer, S. A. (2010) Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse Mol. Endocrinol. 24, 2050-64
8. Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., and Kuro-o, M. (2007) Tissue-specific expression of beta-Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 J. Biol. Chem. 282, 26687-95
9. Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D. S., Mehrbod, F., Jaskunas, S. R., and Shanafelt, A. B. (2005) FGF-21 as a novel metabolic regulator J. Clin. Invest. 115, 1627-35
10. Wente, W., Efanov, A. M., Brenner, M., Kharitonenkov, A., Koster, A., Sandusky, G. E., Sewing, S., Treinies, I., Zitzer, H., and Gromada, J. (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways Diabetes 55, 2470-8
11. Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S. C., Graham, M., Busby, J., Hecht, R., Li, Y. S., Li, Y., Lindberg, R., and Veniant, M. M. (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models - association with liver and adipose tissue effects Am. J. Physiol. Endocrinol. Metab. 297, E1105-14
12. Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y. S., Lindberg, R. A., Chen, J. L., Jung, D. Y., Zhang, Z., Ko, H. J., Kim, J. K., and Veniant, M. M. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice Diabetes 58, 250-9
13. Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y. F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., and Etgen, G. J. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 Endocrinology 148, 774-81
14. Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., and Kharitonenkov, A. (2008) Fibroblast growth factor 21 corrects obesity in mice Endocrinology 149, 6018-27
15. Hecht, R., L., Y., Sun, J., Belouski, E., Hall, M., Hager, T., Yie, J., Wang, W., Winters, D., Smith, S., Spahr, C., Tam, L. T., Shen, Z., Stanislaus, S., Chinookoswong, N., Lau, Y., Sickmier, A., Michaels, M. L., Boone, T., Véniant, M. M., and Xu, J. (2012) Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes PLOS One 7 (11) e49345
16. Mu, J., Pinkstaff, J., Li, Z., Skidmore, L., Li, N., Myler, H., Dallas-Yang, Q., Putnam, A.-M., Yao, J., Bussell, S., Wu, M., Norman, T. C., Rodriguez, C. G., Kimmel, B., Metzger, J. M., Manibusan, Al., Lee, D., Zaller, D. M., Zhang, B. B., DiMarchi, R. D., Berger, J. P., and Axelrod, D. W. (2012) FGF21 Analogues of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents Diabetes 61 (2) 505-512
17. Harris, J. M. and Chess, R. B. (2003) Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discovery 2, 214-221
18. Jain, A. and Jain, S. K. (2008) PEGylation: an approach for drug delivery Crit. Rev. Ther. Drug Carrier Syst. 25 (5) 403-447
19. Veronese, F. M. and Mero, A. (2008) The impact of PEGylation on biological therapies BioDrugs 22 (5) 315-329
20. Bendele, A., Seely, J., Richey, C., Sennello, G., and Shopp, G. (1998) Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins Toxicol. Sci. 42, 152-157
21. Webster, R., Didier, E., Harris, P., Seigel, N., Stadler, J., Tilbury, L., and Smith, D. (2007) PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies Drug Metab. Dispos. 35, 9-16
22. Fiser, A. and Sali, A. (2003) Modeler: generation and refinement of homology-based protein structure models Methods Enzymol. 374, 461-491
23. Emsley, P. and Cowtan, K. Coot (2004) Model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 2126-2132
24. Yie, J., Hecht, R., Patel, J., Stevens, J., Wang, W., Hawkins, N., Steavenson, S., Smith, S., Winters, D., Fisher, S., Cai, L., Belouski, E., Chen, C., Michaels, M. L., Li, Y. S., Lindberg, R., Wang, M., Véniant, M., and Xu, J. (2009) FGF21 N- and C-termini play different roles in receptor interaction and activation FEBS Lett. 583, 19-24
25. Beckman, J. S., Minor, R. L., Jr, White, C. W., Repine, J. E., Rosen, G. M., and Freeman, B. A. (1998) Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance J. Biol. Chem. 263, 6884-6892
26. Bolon, B., Faust, J., and Storm, N. 2001, Cytoplasmic vacuoles in renal tubular epithelium of mice given polyethylene glycol (PEG) conjugated protein are reduced by altering PEG size and conformation [abstract] Toxicologist 60, 376
27. Brandt, E. J., Elliott, R. W., and Swank, R. T. (1975) Defective lysosomal enzyme secretion if kidneys of Chediak-Higashi (beige) mice J. Cell Biol. 67, 774-788
28. Vogetseder, A., Karadiniz, A., Kaissling, B., and Le Hir, M. (2005) Tubular cell proliferation in the healthy rat kidney Histochem. Cell Biol. 124, 97-104
29. Boldt, J., Brosch, C., Ducke, M., Papsdorf, M., and Lehmann, A. (2007) Influence of volume therapy with a modern hydroxyethystarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin Crit. Care Med. 35 (12) 2740-2746
30. Dickenmann, M., Oetti, T., and Mihatsch, M. J. (2008) Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes Am. J. Kidney Dis. 51, 491-503